Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial - Clarke, N; Wiechno, P; Alekseev, B (The Lancet Oncology, 2018)
et al.